Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.30 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10521310 | 0.80 | GAA (0.47) | KMT2AMAPTHRH4 | |
| SCHEMBL11103519 | 0.79 | — | — | |
| SCHEMBL31491478 | 0.79 | PLA2G7 (0.36) | KMT2AALDH1A1BRD4 | |
| SCHEMBL10518622 | 0.78 | CYP2A6 (0.45) | ALDH1A1MAPT | |
| SCHEMBL28060781 | 0.76 | NPC1 (0.36) | KMT2AMAPT | |
| SCHEMBL3793801 | 0.73 | CRHBP (0.34) | KMT2AALDH1A1CRHBPCRHR2 | |
| SCHEMBL18967438 | 0.69 | PTGS1 (0.34) | KMT2AALDH1A1BRD4MAPTMAOA | |
| SCHEMBL11090349 | 0.68 | — | — | |
| SCHEMBL21861302 | 0.67 | TRPV4 (0.39) | — | |
| SCHEMBL6380762 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6232326-B1 | SUFFICIENT TO REDUCE DOPAMINE LEVELS IN SUBCORTICAL AREAS OF THE BRAIN WITHOUT CAUSING SYMPTOMS OF PARKINSON'S DISEASE; PERMANENT OR LONG-TERM AMELIORATION OF SYMPTOMS | ALPHA RESEARCH GROUP, LLC | 2001-05-15 | — | — | US | claimed |
| US-20210028368-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-01-28 | — | — | US | disclosed |
| EP-3322693-B1 | A PLURALITY OF HOST MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM & HAAS ELECT MATERIALS KOREA LTD (KR) | 2020-02-12 | — | — | EP | disclosed |
| WO-2017078403-A1 | A PLURALITY OF HOST MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2017-05-11 | — | — | WO | disclosed |
| CN-102883607-B | Compounds for the treatment of cancer | GTX INC | 2015-07-22 | — | — | CN | disclosed |
| WO-2015046916-A1 | A COMBINATION OF A HOST COMPOUND AND A DOPANT COMPOUND | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2015-04-02 | — | — | WO | disclosed |
| US-20010020013-A1 | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp | GUILFORD PHARMACEUTICALS, INC. | 2001-09-06 | — | — | US | disclosed |
| US-6232326-B1 | SUFFICIENT TO REDUCE DOPAMINE LEVELS IN SUBCORTICAL AREAS OF THE BRAIN WITHOUT CAUSING SYMPTOMS OF PARKINSON'S DISEASE; PERMANENT OR LONG-TERM AMELIORATION OF SYMPTOMS | ALPHA RESEARCH GROUP, LLC | 2001-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210028368-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | EHD1, HVCN1, CRY1 | KMT2A 1783/4885ALDH1A1 23/4885BRD4 1647/4885 |
| US-20010020013-A1 | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp | PARP3, PARP1, PARP2 | KMT2A 1946/4885ALDH1A1 373/4885BRD4 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.